CVE:TAK Takeda Pharmaceutical (TAK) Stock Price, News & Analysis → Massive Crisis Looming — Protect Your Savings Now (From Weiss Ratings) (Ad) Free TAK Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume143,897 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Takeda Pharmaceutical alerts: Email Address Ad Behind the MarketsProtect Your Bank Account from ChinaChina is set to launch a gold-backed currency that could shake the financial world. This move will give them unprecedented power over global finance. And could divert trillions from U.S. Treasury bonds.Discover these 4 simple steps here >>> About Takeda Pharmaceutical Stock (CVE:TAK)The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.Read More Ad Behind the MarketsProtect Your Bank Account from ChinaChina is set to launch a gold-backed currency that could shake the financial world. This move will give them unprecedented power over global finance. And could divert trillions from U.S. Treasury bonds.Discover these 4 simple steps here >>> TAK Stock News HeadlinesMay 29, 2024 | msn.comTakeda layoff plans follow $1.87 milllion tax incentive awardMay 28, 2024 | msn.comTell us: Are you a current or former Takeda employee? We want to hear about it.May 21, 2024 | tmcnet.comCOUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical OfficerMay 10, 2024 | msn.comCatalyst's New CEO Has Big Ideas For The Small BiotechMay 10, 2024 | bizjournals.comTakeda kicks off multi-year revamp. What's it mean for Mass. employees?May 9, 2024 | finance.yahoo.comTakeda targets ‘efficiency’ in restructuring, pipeline cutsMay 9, 2024 | bloomberg.comTakeda Aims to Boost Growth With $900 Million Tech OverhaulMay 9, 2024 | morningstar.comTakeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss — UpdateMay 9, 2024 | msn.comTakeda Pharmaceutical Non-GAAP EPS of ¥484.00, revenue of ¥4263.8B; initiates FY24 outlookMay 9, 2024 | msn.comTakeda Pharmaceutical Projects Lower Annual Profit After Quarterly LossMay 2, 2024 | msn.comPharma executive challenges firm’s disciplinary process over allegations of unwanted sexual advances towards female colleague at Christmas partyApril 26, 2024 | lse.co.ukHutchmed notes CHMP's positive opinion for fruiquintinib approvalApril 25, 2024 | seekingalpha.comNeurocrine: Success Continues To Roll In With Positive MDD Treatment DataApril 24, 2024 | finance.yahoo.comAAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meetingApril 23, 2024 | msn.comNeurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive DisorderApril 23, 2024 | msn.comNeurocrine succeeds in mid-stage trial for Takeda-partnered depression drugApril 23, 2024 | finance.yahoo.comTakeda Pharmaceutical: A Long-Term Cash CowApril 22, 2024 | msn.comTop pharmaceutical company evaluates Optimer for precision liver medicineApril 18, 2024 | investing.comFDA approves Takeda's ENTYVIO for Crohn's diseaseApril 18, 2024 | markets.businessinsider.comFDA Approves Subcutaneous Administration Of Takeda's Entyvio For Crohn's DiseaseApril 18, 2024 | marketwatch.comTakeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's DiseaseApril 18, 2024 | finance.yahoo.comTakeda Pharmaceutical Company Limited (TKD.VI)April 15, 2024 | seekingalpha.comJazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay OffApril 12, 2024 | bizjournals.comViewpoint: To stay on top, Boston must lead pharma’s transformationApril 11, 2024 | benzinga.comAssessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals IndustrySee More Headlines Receive TAK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorManufacturing Industry Medicinal & Botanical Manufacturing Sub-IndustryN/A Current SymbolCVE:TAK CUSIPN/A CIKN/A Webwww.takugold.com Phone+1-604-6420115FaxN/AEmployees2,021Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesGilles DessureauInterim PresidentGregory Donald HayesInterim Chief Financial Officer, Corporate SecretaryPeter BuresDirectorDennis Gordon FentieDirectorJanet Lee-SheriffDirectorLori WaltonDirectorC.F. Wasser IIIDirectorMore ExecutivesKey CompetitorsHigh TideTSE:HITINovus EnergyCVE:NVS(EDW.V)CVE:EDW(FSN.V)CVE:FSN(FTE.V)CVE:FTEView All Competitors TAK Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Takeda Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Pure Gold Mining (PGM), Valhi (VHI) and Fission Uranium (FCUUF). How do I buy shares of Takeda Pharmaceutical? Shares of TAK stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:TAK) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.